The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.
Open accessAbstract
The phenotype of T cells therapeutically effective in immunotherapy of advanced Friend virus-induced (FBL) leukemia in vivo and cytotoxic to FBL in vitro was determined. Mice bearing disseminated FBL leukemia were successfully treated by a combination of cyclophosphamide and adoptive transfer of syngeneic immune lymphocytes. Therapeutic efficacy was largely dependent on the presence of Lyt-1+2- T cells in the transferred cells, whereas cells cytotoxic to FBL tumor in vitro were derived from the Lyt-1+2+ and Lyt-1-2+ subsets. Thus, the predominate cell required to eradicate tumor in adoptive chemoimmunotherapy was not cytolytic to tumor in vitro. Potentially, the Lyt-1+2- cell may operate in vivo as an amplifier cell rather than by a direct anti-tumor effect. Elimination of the Lyt-1+ population with alpha-Lyt-1 and complement prevented the generation of significant cytotoxic responses during both primary in vitro sensitization to alloantigens and in vitro sensitization of tumour-primed cells. The capacity of Lyt-1+ cell-depleted population to generate cytotoxic responses was partially reconstituted by addition, at the initiation of culture, of interluekin 2, a T cell growth factor derived from Lyt-1+2- cells, which contain the CTL and CTL precursors, were nearly as effective in vitro as unseparated immune cells. If the remaining effector cells (i.e., Lyt-1+2- T cells) function in vivo predominantly as amplifier cells, than the tumour-bearing host must be capable of making a positive contribution to the outcome of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ledbetter, J. A., Rouse, R. V., Micklem, H. S., & Herzenberg, L. A. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.152.2.280 · Cited by 566
Berendt, M. J., & North, R. J. (1980) · The Journal of experimental medicine · doi:10.1084/jem.151.1.69 · Cited by 369
Fujimoto, S., Greene, M. I., & Sehon, A. H. (1976) · PubMed · Cited by 340
The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes.
Gillis, S., Union, N. A., Baker, P. E., & Smith, K. A. (1979) · The Journal of experimental medicine · doi:10.1084/jem.149.6.1460 · Cited by 269
Passive Immunotherapy of Cancer in Animals and Man
(1977) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60637-5 · Cited by 243
Murine Lymphocyte Surface Antigens
Mckenzie, I. F. C., & Potter, T. (1979) · Advances in Immunology · doi:10.1016/s0065-2776(08)60263-1 · Cited by 226
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever, M. A., Greenberg, P. D., & Fefer, A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.711 · Cited by 118
Self-citationBerenson, J. R., Einstein, A. B., & Fefer, A. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.1.234 · Cited by 83
Self-citation
Cited by
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Beyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732
Down-Regulation of the Antitumor Immune Response
(1985) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60265-1 · Cited by 682
North, R. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1063 · Cited by 650
Metadata
- Authors
- Greenberg, P. D., Cheever, M. A., & Fefer, A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1981-09-01
- Volume
- 154
- Issue
- 3
- Pages
- 952-963
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2056346648
- Cited by
- 312
- References
- 8
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.